Lexicon Pharmaceuticals to Participate in the Citi 15ᵗʰ Annual BioPharma Virtual Conference and the Wells Fargo 2020 Virtu...
September 03 2020 - 6:00PM
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its
participation in the following conferences:
- Citi 15th Annual BioPharma Virtual Conference on Wednesday,
September 9, 2020
- Wells Fargo 2020 Virtual Healthcare Conference on Thursday,
September 10, 2020
Jeffrey L. Wade, Lexicon’s executive vice
president, corporate and administrative affairs and chief financial
officer, will make a live webcast company presentation for the
Wells Fargo conference on Thursday, September 10, 2020 at 2:00 p.m.
ET. The webcast will be available in the “Events” section of
the Lexicon website at www.lexpharma.com. An archived version of
the webcast will be available on the website for two weeks.
About Lexicon
Pharmaceuticals
Lexicon is a fully integrated biopharmaceutical
company with a mission of pioneering medicines that transform
patients’ lives. Through its Genome5000™ program, Lexicon
scientists studied the role and function of nearly 5,000 genes and
identified more than 100 protein targets with significant
therapeutic potential in a range of diseases. Through the precise
targeting of these proteins, Lexicon is pioneering the discovery
and development of innovative medicines to safely and effectively
treat disease. In addition to its first commercial product,
XERMELO®, Lexicon has a pipeline of promising drug candidates in
clinical and preclinical development in diabetes and metabolism,
oncology, neuropathic pain and other indications. For additional
information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking
statements,” including statements relating to Lexicon’s growth and
future operating results, discovery and development of products,
strategic alliances and intellectual property, as well as other
matters that are not historical facts or information. All
forward-looking statements are based on management’s current
assumptions and expectations and involve risks, uncertainties and
other important factors, specifically including those relating to
Lexicon’s ability to meet its capital requirements, successfully
conduct preclinical and clinical development of its drug
candidates, obtain necessary regulatory approvals, achieve its
operational objectives, obtain patent protection for its
discoveries and establish strategic alliances, as well as
additional factors relating to manufacturing, intellectual property
rights, and the therapeutic or commercial value of its drug
candidates, that may cause Lexicon’s actual results to be
materially different from any future results expressed or implied
by such forward-looking statements. Information identifying such
important factors is contained under “Risk Factors” in Lexicon’s
annual report on Form 10-K for the year ended December 31, 2019, as
filed with the Securities and Exchange Commission. Lexicon
undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise.
For Inquiries:
Chas SchultzExecutive Director, Corporate
Communications and Patient AdvocacyLexicon Pharmaceuticals(281)
863-3421 cschultz@lexpharma.com
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Apr 2023 to Apr 2024